HeartSciences (HSCS) Stock: Buy, Sell, or Hold?
HSCS - HeartSciences Inc. Common Stock
$3.89
-0.29 (-6.94%)
▼
5d:
-15.98%
30d:
+24.68%
90d:
+39.43%
WAIT
LOW Confidence
Analysis Updated: Sep 30, 2026 12:00 AM ET
Earnings: Sep 10, 2026
0d
Get Alerted When HSCS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: HSCS is down 16.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: HSCS is down 16.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: HSCS is currently trading at $3.89, which is considered fair relative to its 30-day fair value range of $3.14 to $4.50.
Technical Outlook: Technically, HSCS is in a strong uptrend. The price is currently testing key support at $3.80. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: HSCS scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+187.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HSCS is in a strong uptrend. The price is currently testing key support at $3.80. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: HSCS scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+187.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.14 -
$4.50
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
44.7%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (8/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.9%)
- BULLISH: Trading 187.1% below Wall St target ($12.00)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.14 -
$4.50
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.80
Resistance Level
$5.25
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.48
Wall Street Target
$12.00
(+187.1%)
Revenue Growth (YoY)
10.5%
Share & Embed Analysis
Last updated: October 01, 2026 5:01 PM ET
Data refreshes hourly during market hours. Next update: 6:01 PM
Data refreshes hourly during market hours. Next update: 6:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HSCS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$61 | 62 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$369 | 64 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 48 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 49 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 44 HOLD |
